Agilent Technologies introduced SureSelect Human All-Exon V5 and V5 + UTRs for next-generation sequencing. The new all-exon solutions incorporate the latest advances from Agilent Genomics, the ...
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback